Quest PharmaTech (TSXV:QPT) Change In Receivables : C$-0.01 Mil (TTM As of Oct. 2023)

View and export this data going back to 1999. Start your Free Trial

What is Quest PharmaTech Change In Receivables?

Quest PharmaTech's change in receivables for the quarter that ended in Oct. 2023 was C$0.00 Mil. It means Quest PharmaTech's Accounts Receivable stayed the same from Jul. 2023 to Oct. 2023 .

Quest PharmaTech's change in receivables for the fiscal year that ended in Jan. 2023 was C$-0.22 Mil. It means Quest PharmaTech's Accounts Receivable increased by C$0.22 Mil from Jan. 2022 to Jan. 2023 .

Quest PharmaTech's Accounts Receivable for the quarter that ended in Oct. 2023 was C$0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Quest PharmaTech's liquidation value for the three months ended in Oct. 2023 was C$-1.07 Mil.

Quest PharmaTech Change In Receivables Historical Data

The historical data trend for Quest PharmaTech's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quest PharmaTech Change In Receivables Chart

Quest PharmaTech Annual Data

Trend

Jan14

Jan15

Jan16

Jan17

Jan18

Jan19

Jan20

Jan21

Jan22

Jan23

Change In Receivables

Get a 7-Day Free Trial

0.01

-0.02

0.03

-0.22

Quest PharmaTech Quarterly Data
	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23
Change In Receivables	Get a 7-Day Free Trial															-0.21	-0.01	-	-	-

Quest PharmaTech Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Oct. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.01 Mil.

Quest PharmaTech (TSXV:QPT) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Quest PharmaTech's Days Sales Outstanding for the quarter that ended in Oct. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Quest PharmaTech's accounts receivable are only considered to be worth 75% of book value:

Quest PharmaTech's liquidation value for the quarter that ended in Oct. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.094	-	1.165	+	0.75 * 0	+	0.5 * 0
=	-1.07

Quest PharmaTech Change In Receivables Related Terms

Thank you for viewing the detailed overview of Quest PharmaTech's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Quest PharmaTech (TSXV:QPT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Quest PharmaTech Inc (TSXV:QPT) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

8123 Roper Road NW, Edmonton, AB, CAN, T6E 6S4

Website

http://www.questpharmatech.com

Quest PharmaTech Inc is a Canadian-based pharmaceutical company developing targeted cancer therapy with its lead product MAb AR9.6, under development for a novel target- truncated O-glycans on MUC16 discovered at the University of Nebraska Medical Center. The company is also developing products utilizing proprietary transdermal delivery technologies with a focus on dermatology and wound healing applications.

Executives

Ragupathy Madiyalakan

Director

Quest PharmaTech (TSXV:QPT) Headlines

No Headlines